Epidemiology and treatment of post-stroke depression

Abstract

Mood depression is a common and serious complication after stroke. According to epidemiological studies, nearly 30% of stroke patients develop depression, either in the early or in the late stages after stroke. Although depression may affect functional recovery and quality of life after stroke, such condition is often ignored. In fact, only a minority of patients is diagnosed and even fewer are treated in the common clinical practice. Moreover, the real benefits of antidepressant (AD) therapy in post-stroke depression have not been fully clarified. In fact, controlled studies on the effectiveness of ADs in post stroke depression (PSD) are relatively few. Today, data available suggest that ADs may be generally effective in improving mood, but guidelines for the optimal treatment and its length are still lacking.

The progressive decrease in stroke mortality observed in Western countries, in the last decades, and the subsequent increase of survivors with residual impairments and disabilities (Sarti et al 2000), have been accompanied by a growing interest in factors that could interfere with functional outcome and quality of life (QoL). In light of this, a crucial role is played by post-stroke depression (PSD).

In particular, mood depression is considered as the strongest predictor of QoL in stroke survivors (Kim et al 1999; King 1996). Moreover, PSD is associated with an increased disability (Schwartz et al 1993; Herrmann et al 1998; Ramasubbu et al 1998; Kotila et al 1999; Pohjasvaara et al 2001), increased cognitive impairment (Kauhanen et al 1999), increased mortality, both on short and long term (Morris et al 1993; Schulz et al 2000; House et al 2001; Williams et al 2004), increase risk of falls (Jorgensen et al 2002) and, finally, with worse rehabilitation outcome (Sinyor et al 1986; Paolucci et al 1999, 2001; van de Weg et al 1999; Gillen et al 2001). Conversely, the absence of PSD in young adults is a significant predictor of the ability to return to work (Neau et al 1998). Moreover, an improvement of depressive symptoms has been associated with a better functional recovery (Chemerinski et al 2001).

In spite of the relative large number of papers available on PSD, it is surprising to note that the attention of authors has been focused on epidemiological features and impact of PSD both on functional outcome and QoL than on possible therapeutic approaches.

This review concerns a literature evaluation on epidemiological and therapeutic aspects of PSD. Relevant articles related to depression and cerebrovascular diseases selected from computer-based search have been examined using the Medline database from 1975 to August 2007.

Epidemiological dimension and methodological problems

Today, in spite of the abundant literature available on this topic, it is still difficult to define the real prevalence rate of PSD, essentially because of the weak concordance across studies. This relevant variability arises not only from methodological problems of the investigations (differences in study populations and the timing of assessments) but also from the complexity in recognition, assessment, and diagnosis of depression.

In fact, as shown in the Table 1, there is a large variability of diagnostic tools used for the detection of PSD. In fact, while most of the studies based the diagnosis on cutoff score in different rating scales, others followed a structured interview and the diagnostic standards defined by DSM (Diagnostic and statistical manual of mental disorders)-III, III-R, and IV, and some studies even based their assessment only on clinical findings.

Table 1.

Prevalence of PSD according to time and setting of evaluation

Authors	n	Population	Country	Time	Criteria	%
Folstein et al 1977	20	Rehab hosp	USA	1 m	HDRS/PSE	45
Robinson et al 1981	18	hospital-based	USA	<1 m	HDRS, ZSRDS	61
Feibel et al 1982	91	outpatient	USA	6 m	Nursing evaluation	26
Robinson et al 1983	103	hospital-based	USA	1 m	HDRS, PSE,DSM-III	47
Sinyor et al 1986	64	Rehab hosp	CND	<2 m	ZSRDS	47
Ebrahim et al 1987	149	hospital-based	UK	6 m	GHQ	23
Wade et al 1987	379 377 348	Community	UK	<1 m 6 m 12 m	WDI	22 20 18
Eastwood et al 1989	87	Rehab hosp	CND	21 d- 6 m	HDRS, GDS	50
Finset et al 1989	42	Rehab hosp	Norway	6 m	GCRD	36
Malec et al 1990	20	Rehab hosp	USA	1 m	HDRS	35
Morris et al 1990	99 56	rehab hosp	AU	2 m 15 m	MADRS/CIDI	35 12
Parikh et al 1990	63	hospital-based hospital-based	USA	<1 m 2 y	HDRS, PSE,DSM-III	39 39
Fedoroff et al 1991	205	hospital-based	USA	<1 m	HDRS, PSE,DSM-III	41
House et al 1991	89 119 112	community	UK	1 m 6 m 12 m	PSE, DSM-III	23 20 16
Schubert et al 1992	18	rehab hosp	USA	1.5 m	BDI, DSM-III	72
Astrom et al 1993	80 77 73 57 49	hospital-based	SW	2 m 3 m 1 y 2 y 3 y	DSM-III	25 31 16 19 29
Schwartz et al 1993	91	rehab hosp	USA	7 m	DSM-III	40
Andersen et al 1994	285 285	hospital-based	DK	1 m 1 y	HDRS	21 41
Burvill et al 1995	294	community	AU	4 m	PSE, DSM-III	23
Diamond et al 1995	14	rehab hosp	USA		GDS	36
Gonzalez-Torrecillas et al 1995	130	rehab hosp	Belgium	1 m	HDRS, MADRS	37
Wilkinson et al 1997	96	community	UK	5 y	HADS	36
Ng et al 1995	52	rehab hosp	Singapore	<1 m	DSM-III-R	55
Herrmann et al 1998	150 133	hospital-based	CND	3 m 1 y	MADRS	27 22
Pohjasvaara et al 1998	277 276	hospital-based	FIN	3 m 15 m	DSM-III-R	40 45
Neau et al 1998	71	outpatient		>1 y	MADRS/DSM-III	48
Kotila et al 1999	321 311	community	FIN	3 m 12 m	BDI	47 47
Kellermann et al 1999	82	hospital-based	Hungary	1 w	BDI	15
Gainotti et al 1999	153 153	rehab hosp	Italy	2 m 4 m	HDRS	32 60
Kauhanen et al 1999	106	rehab hosp	FIN	3 m	PSE, DSM-IIII-R	53
Paolucci et al 1999	470	rehab hosp	Italy	1.5 m	HDRS	27
van de Weg et al 1999	85	rehab hosp	Netherlands	20–40 d	DSM-III-R	35
Berg et al 2001	89	hospital-based	FIN	<1 m	BDI	27
Gillen et al 2001	243	rehab hosp	USA	<1 m	GDS	13
Vataja et al 2001	275	outpatient	FIN	3 m	PSE, DSM-IIII-R	40
Tang et al 2002	157	rehab hosp	China	1 m	DSM-III-R	17
Aben et al 2002	154 154	hospital-based	Netherlands	1 m 2 y	DSM-IV DSM-IV	22 39
Eriksson et al 2004	15747	community	Sweden	3 m	Self reported	14
Cassidy et al 2004	50	rehab hosp	Ireland	6 m	DSM-IV, HDRS	20
Mast et al 2004	195	rehab hosp	USA	<1 m	DSM-III-R	36
Verdelho et al 2004	110 96 71 73	outpatient	France	6 m 1 y 2 y 3 y	MADRS	43 36 24 18
Vataja et al 2004	70	outpatient	FIN	3 m	PSE, DSM-IIII-R	37
Naess et al 2005	196	outpatient	Norway	6 y	MADRS	29
Paul et al 2006	441	outpatient	Australia	5 y	IDAS	17
Hackett et al 2006	739	community	NZ	6 m	GHQ	27
Jia et al 2006	5825	hospital-based, retrospective	USA	1 y	clinical	41
Paolucci et al 2006	1064 821	hospital-based	Italy	1 m 9 m	BDI, DSM-IV	22 36
Townend et al 2007	125 125	hospital-based	Australia	1 m 3 m	HADS HADS	16 21
van de Port et al 2007	165	outpatient	Netherlands	3 y	CES-D	19
Linden et al 2007	149	outpatient	Sweden	20 m	DSM-III-R	34
Brodaty et al 2007	164 164	hospital-based outpatient	Australia Australia	3 m 15 d	DSM-III-R DSM-IV	12 21

Abbreviations: d, days; m, months; y, years; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; CIDI, Composite International Diagnostic Interview; DSM, Diagnostic and Statistical Manual of Mental Disorder; GCRD, Global Clinical Rating of Depressed mood; GDS, Geriatric Depression Scale; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating Scale; IDAS, Irritability, Depression and Anxiety Scale; PSE, Present State Examination; WDI, Wakefield Depression inventory; ZSRDS, Zung Self Rating Depression Scale.

Moreover, assessment of depression in stroke survivors may be often laborious and the risk of inappropriate diagnosis (under- or overdiagnosing) is high (Fedoroff et al 1991). In fact, PSD may not only be overdiagnosed because of somatic symptoms caused by medical illness, but also underdiagnosed, particularly in patients with cognitive impairment. Another problem, as observed by Schubert and coworkers (1992), may be the inadequacy of physicians without a proper psychiatric training (Schubert et al 1992). The correct attribution of somatic symptoms (psychomotor retardation, and disturbances in appetite, sleep, and sexual interest) to either PSD or stroke is a very relevant problem, because such symptoms may affect rating scales, as Hamilton Depression Rating Scale (HDRS), Montgomery Asberg Depression Rating Scale (MADRS), or Beck Depression Inventory (BDI), and also because they are among DSM criteria. It is important to remember that rating scales were designed to measure depression severity in primary depressive illness, rather than to diagnose depression, in particular for depression in comorbidity. Furthermore, DSM criteria for classification of disorders, (temporal criteria, in particular)are not always satisfied for dysthymia and major depression. So, we found cases diagnosed as major depression even in reports on PSD in settings characterized by short hospital stay, such as stroke units (Kellermann et al 1999; Berg et al 2001). Additionally, other relevant points, as evaluation-time after stroke (acute vs. chronic patients) and variability of the study setting (in-patients, outpatients, patients bedridden in rehabilitation structures, community), minimize the possibility of a generalization. Lastly, the problem of aphasia should be kept in mind. The exclusion of aphasic patients, because of the evident difficulty in evaluating depressive symptoms, reported in several of studies examined, may be an important confounding variable (Carson et al 2000). However, there is no concordance on frequency of PSD in aphasics, observed either in low (15%) (Damecour and Caplan 1991), in middle (24%) (Laska et al 2007) and in high percentage (70% at 3 months and 62% at 12 months after stroke) of cases (Kauhanen et al 2000).

A recent meta-analysis, evaluating data from studies conducted between 1977 and 2002, estimated the pooled frequency at 33% (95% confidence interval, 29% to 36%) (Hackett et al 2005b), even if with relevant differences across studies. In particular, the pooled estimate from the population-based studies was equal in the acute and medium-term phases (33%), with a slight increase to 34% in the long-term phase of recovery after stroke. Moreover, there were only slight differences in the pooled frequencies in the hospital-based (acute 36%, medium-term 32%, and long-term 34%) and rehabilitation-based studies (acute 30%, medium 36%, and long-term 34%) over time.

Studies available after the publication of that report confirmed that PSD is generally observed in nearly one third of cases (Vataja et al 2004; Verdelho et al 2004; Paolucci et al 2006; Linden et al 2007; Townend et al 2007). However, a certain degree of variability in the percentages was observed in those reports, too. In particular, the percentage of depression observed in the Sidney Stroke Study was lower than in the previous ones (Brodaty et al 2007). Moreover, recent longitudinal studies observed not only that frequency PSD increases in prevalence over the initial weeks post-stroke, in particular within three months from stroke, despite an improvement in disability (Andersen et al 1994b; Aben et al 2003; Paolucci et al 2006), but also that patients with early onset PSD were not necessarily affected later and vice versa, indicating the dynamic nature of PSD in the early stages.

Only few epidemiological data on vascular depression are available today. Vascular depression is a new diagnostic concept based on hypothesis that chronic ischemic damage is an important cause of depression in the elderly. This concept initially emerged from the finding that patients with late-onset depression had higher rate of encephalomalacia or hyperintensities observed with magnetic resonance imaging (MRI) compared with patients with early-onset depression (Hickie et al 1995), and was later formulated by Alexopoulos and coworkers in 1997. These authors hypothesized that cerebrovascular disease can predispose, precipitate, or perpetuate a depressive syndrome in older adults (Alexopoulos et al 1997a). Affected individuals display more apathy, retardation, and lack of insight, and less agitation and guilt than do elderly individuals who are depressed without vascular risk factors, on one hand, and also greater disability and cognitive impairment, on the other (Alexopoulos et al 1997b). Mast and coworkers reported vascular depression in nearly 35% (35.2%) of patients with cerebrovascular risk factors admitted in geriatric rehabilitation, but without clinical evidence of stroke (Mast et al 2004). In that study, a positive association was established between depression and increasing percentage of cerebrovascular risk factors (Mast et al 2004). Furthermore, patients with depression and subcortical vascular lesions have poor response to antidepressants (Simpson et al 1998), while might be effective dopamine acting agents or norepinephrine enhancing agents (Alexopoulos 2006). Thus, should vascular depression be recognized as a separate psychiatric disorder or as a diagnostic subtype of major depressive disorder? Indeed, Alexopoulos refined the notion of vascular depression, proposing a depression executive dysfunction (DED) disorder of late-life, but only on the basis of clinical criteria and regardless the etiology (Alexopoulos 2001), while Taylor and coworkers (2006) proposed subcortical ischemic depression as specific entity. On the other hand, while the former may be caused by vascular disease, the latter requires a subcortical vascular impairment. Further researches are needed to clarify these and other doubts.

Treatment studies

Although antidepressant (AD) drugs have been discovered many decades ago [monoamine oxidase inhibitors (MAOIs) in the 1950s, tricyclic antidepressant (TCA) imipramine in 1957 and first selective serotonin reuptake inhibitor (SSRI), fluoxetine in 1988], most patients today do not receive an effective specific treatment. The attitude that PSD is a natural and inevitable condition which is not important to treat seems still common. General opinion appears to be that depression improves if the patient’s physical condition improves (Gustafson et al 1995). Moreover, physicians are often reluctant to prescribe ADs to older patients with relevant physical illnesses (House et al 1989), because of the perceived risk of side effects especially on the cardiovascular system, fear of drug interactions in multiple comorbidity, and poor experience of depression treatment in the elderly. However, a recent systematic review of 18 randomized controlled trials comparing any AD drug with placebo or no treatment in depressed adults with a specified physical disorder showed that ADs cause improvement in depressive symptoms in patients with a wide range of physical diseases (Gill and Hatcher 1999). In spite of these data, not only the studies on therapeutic approaches on PSD are relatively scarce, but also most of studies reported the effects of AD drugs only on mood disturbance. In fact, even if some authors suggested the favorable effect of AD drugs on functional recovery (Fedoroff and Robinson 1989), there are only few studies that evaluated the impact of ADs on functional outcome and rehabilitation results (Reding et al 1986; Fedoroff and Robinson 1989; Gonzalez-Torrecillas et al 1995; Dam et al 1996; Miyai and Reding 1998; Paolucci et al 1999; Gainotti et al 2001; Paolucci et al 2001).

Table 2 reports the percentages of patients treated with ADs in papers regarding prevalence and clinical impact of PSD.

Table 2.

Percentages of patients treated with antidepressant in studies on prevalence of PSD

Authors	n	Population	Country	% patients treated
Sinyor et al 1986	64	Rehab hosp	CND	33
Ebrahim et al 1987	149	hospital-based	UK	15
Parikh et al 1990	63	hospital-based	USA	8
Herrmann et al 1998	150	hospital-based	Canada	19
Pohjasvaara et al 1998	277	hospital-based	FIN	39
Kotila et al 1999	321	community	FIN	17
Kauhanen et al 1999	106	rehab hosp	FIN	36
Paolucci et al 1999	470	rehab hosp	Italy	100
van de Weg et al 1999	85	rehab hosp	Netherlands	20
Eriksson et al 2004	15747	community	Sweden	49
Cassidy et al 2004	50	rehab hosp	Ireland	60
Paul et al 2006	441	outpatient	Australia	22
Paolucci et al 2006	1064	hospital-based	Italy	49
Jia et al 2006	5825	hospital-based, retrospective	USA	63

The choice of optimal treatment

There is relatively little comparative information on how to make the choice of one AD over another, and none at all specific to PSD. Today, SSRIs are the recommended pharmacotherapy of PSD for their favorable tolerability profile (Turner-Stokes and Hassan 2002; SPREAD 2005). In fact, the affinity of TCAs for a number of central receptors including muscarinic cholinergic and histaminergic receptors makes them not recommended as first-line choice for treatment of PSD. Conversely, SSRIs have no affinity for cholinergic or histaminergic receptors and thus are generally well tolerated, and do not have cardiovascular or sedative effects. However, the SSRIs are not entirely without side-effects. Gastrointestinal symptoms, headache, sexual dysfunction and insomnia are relatively common. Arguably, the most important difference between the SSRIs lays in their potential to cause drug- drug interactions through inhibition of cytochrome-P450 isoforms, which is different for each SSRI. Thus, fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor; fluoxetine and paroxetine are potent CYP2D6 inhibitors; sertraline is a moderate CYP2D6 inhibitor; and citalopram has little effect on the major cytochrome-P450 isoforms (Hemeryck and Belpaire 2002). So, fluvoxamine (CYP1A2 inhibitor) can cause an increase of blood levels of theophyllin or caffeine, while paroxetine and fluoxetine (CYP2D6 inhibitors) an increase of concentration of TCAs or atypical antipsychotics. Knowledge of the CYP-isoforms involved in the metabolism of the co-administered drug may help clinicians to predict and avoid potentially dangerous drug- drug interactions. Expected interactions can usually be managed by appropriate dose adjustments and titration of the drug. Importantly, the use of SSRIs has been associated with increased risk of bleeding complications (Skop and Brown 1996), possibly as a result of inhibition of platelet aggregation (Maurer-Spurej et al 2004). However, in a recent systematic review, Ramasubbu and colleagues (2004) observed that SSRI treatment had a very low rate of cerebrovascular adverse reactions. In particular, two case-control studies mentioned in that review showed no association between SSRI use and intracranial hemorrhage (de Abajo et al 2000; Bak et al 2002).

Nonpharmacological management

Today, the main therapeutic approach of PSD, and in particularly in subacute phase after stroke, is essentially pharmacological. In fact, a psychotherapeutic intervention is not only expensive in terms of staff time and expertise, but also requires several weeks before showing any clinical improvement. This delay may be critical for the outcome in a time-limited course of rehabilitation. Therefore, in the common clinical practice, AD treatment is the most realistic solution, with psychotherapeutic intervention reserved for those in whom ADs are either inappropriate or not tolerated. Regarding the effectiveness of psychotherapeutic interventions, methodological limitations in existing research prevent a conclusion as any psychological intervention has empirical support for its effectiveness (Gordon and Hibbard 1997; Kneebone and Dunmore 2000). On the other hand, cognitive behavioral therapy has shown some promising results that make it worthy of further exploration (Lincoln et al 1997; Lincoln and Flannaghan 2003).

Controlled pharmacological studies

Controlled studies on the effectiveness of ADs in PSD are relatively few, and they are essentially related to the use of TCAs or SSRIs (Table 3). Data on usefulness of new dual-component ADs are still not available, to our knowledge.

Table 3.

Controlled studies on treatment of post-stroke depression

Authors	No	Treatment studied	Design	Time from stroke	Trial length	Outcome measures	Results
Lipsey et al 1984	34	nortryptiline vs placebo	DB	≤18 m	4–6 w	HDRS, ZSRDS	nortriptyline more effective than placebo in reduction of depression
Reding et al 1986	27	trazodone vs placebo	DB	6 w	~4–5 w	ZSRDS	trazodone trend towards better functional status
Andersen et al 1994	66	citalopram vs placebo	DB	2–52 w	16 w	HDRS	citalopram more effective than placebo in reduction of depression
Lauritzen et al 1994	20	Imipramine+mianserin vs desipramine+mianserin	DB	<3 m	6 w	HDRS	Imipramine + mianserin more effective than desipramine + mianserin in reduction of depression
Robinson et al 2000	56	nortryptiline vs fluoxetine vs placebo	DB	4–16 w	12 w	HDRS	nortriptyline produced a significantly higher response rate than fluoxetine or placebo
Wiart et al 2000	31	fluoxetine vs placebo	DB	<3 m	6 w	MADRS	fluoxetine more effective than placebo in reduction of depression
Fruehwald et al 2003	54	fluoxetine vs placebo	DB	<2 w	3 m	HDRS, BDI	fluoxetine more effective than placebo at 18-month follow-up evaluation
Rampello et al 2004	74	citalopram vs reboxetina	DB	<12 m	16 w	HDRS, BDI	citalopram better in anxious depressed patients, reboxetine more effective in retarded depressed patients
Murray et al 2005	123	sertraline vs placebo	DB	3 d – 1y	26 w	MADRS, EDS	sertraline superior only in emotional distress, emotionalism and QoL
Choi-Kwon et al 2006	152	fluoxetine vs placebo	DB	14 m	3 m	BDI, clinical, STAS	fluoxetine more efficacious only in the treatment of emotional incontinence and anger proneness.

Abbreviations: w, weeks; m, months; y, years; DB, double-blind; BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery Asberg Depression Rating Scale; QoL, Quality of Life; STAS, Spielberger Trait Anger Scale.

In a recent Cochrane review, only 7 trials with AD, with a total of 615 patients, entered the meta-analyses (Hackett et al 2004, 2005a). The results of meta-analyses showed that there was evidence of a improvement in depression rating scales, but not in terms of a complete remission of depression following stroke (Hackett et al 2004, 2005a). However, some methodological aspects of this review have been criticized. In particular, Chen and Guo (2006) suggested that the overall effects of AD treatment in term of various depression scores would better be estimated by separating the pretreatment and post-treatment instead of calculating the mean differences. In this fashion, AD treatments were effective in patients after the stroke in term of reducing the symptoms of depression. Moreover, can the concept of remission be applied in patients with depression in comorbidity? In fact, the idea of remission refers to a return to symptom-free state or premorbid levels of functioning (Bakish 2001). Such a model for depression in comorbidity is obviously arduous to obtain, because of the presence of somatic symptoms.

In another recent review, involving six pharmacological studies, there was evidence that ADs significantly improved mood, also in spite of a relevant number of dropouts due to side effects treatment, especially with heterocyclic ADs (Bhogal et al 2005). So, it appears that both TCAs and SSRIs may be effective in the treatment of PSD, although the latter may produce fewer side-effects.

Two randomized, double-blinded, placebo-controlled studies have evaluated the effectiveness of nortriptyline, a tricyclic drug (Lipsey and Robinson 1984; Robinson et al 2000). In the last one, the effectiveness of fluoxetine was also assessed (Robinson et al 2000). In both studies, a significant improvement in depression symptoms was observed in the treated groups as compared to controls. In particular, in the first study a mean baseline to endpoint improvement in HDRS score of 79% was observed in patients treated with nortriptyline as compared with an improvement of 40% in patients treated with placebo (Lipsey and Robinson 1984). In the second study, the mean improvement in HDRS score was higher in depressed patients treated with nortriptyline (60% vs. 9% for patients treated with fluoxetine and 30% with placebo) (Robinson et al 2000). Furthermore, in the study by Robinson and colleagues (2000), but not in that by Lipsey and Robinson (1984), a better recovery in activities of daily living for nortriptyline group was observed. However, there was disagreement regarding drop-out rate: higher among those treated with nortriptyline (38%) in the study by Lipsey and Robinson (1984), and among those treated with fluoxetine (40%) in the study by Robinson and colleagues (2000). However, in this latter study, such high drop-outs rate with fluoxetine might have been due to the relative high dose (up to 40 mg per day) of fluoxetine used (Robinson et al 2000). Moreover, the results of this study fostered the discussion about methodological problems (Van de et al 2003).

Two double-blinded controlled studies have assessed the effectiveness of citalopram, a selective serotonin reuptake inhibitors (SSRI), the first one vs. placebo and the second one vs. noradrenergic drug reboxetine (Andersen et al 1994a; Rampello et al 2004). In both studies, citalopram showed good efficacy and tolerability. In the first study, a mean baseline to endpoint improvement in HDRS score of 45.5% was observed in patients treated with citalopram as compared with an improvement of 16% in patients treated with placebo. Although the drop-out rate was higher in citalopram group, the reported side effects were relatively well tolerated and transient (Andersen et al 1994a). In the second trial, Rampello et al showed that citalopram exhibited greater efficacy in anxious depressed patients, while reboxetine was more effective in retarded depressed patients. No severe side effects were recorded during the study. The drop-out rate was similar between groups, too (three for both treatment) (Rampello et al 2004).

Four studies evaluated the effectives of fluoxetine, another SSRI agent, both on early and late phase after stroke (Robinson et al 2000; Wiart et al 2000; Fruehwald et al 2003; Choi-Kwon et al 2006). The results of these studies are conflicting. In particular, while a positive action on mood even in early phase was observed by Wiart and colleagues (2000), with a mean improvement in MADRS score of 58% for fluoxetine group vs. 31% in placebo group, Fruehwald and coworkers (2003) observed such positive action only in the follow-up. Moreover, Choi-Kwon and colleagues (2006) found that fluoxetine was effective only on emotional incontinence and anger proneness, while Robinson and coworkers (2000) above described a lower effectiveness in comparison with nortriptyline. The drop-out rates were also conflicting: Fruehwald observed no drop-outs during the treatment, Wiart only two (13.3%) in patients treated with fluoxetine, while Choi-Kwon 19.7% in fluoxetine group and 15.8% in placebo group (Wiart et al 2000; Fruehwald et al 2003; Choi-Kwon et al 2006).

Sertraline, another SSRI AD, showed no advantage in comparison to placebo either on major depressive episode or minor depressive disorder (Murray et al 2005). In fact, both groups improved substantially, with no differences between the treatments, either for major depressive episode or minor depressive disorder, or for short- or long-term antidepressant effect and neurologic outcome. However, the compound showed a significantly positive effect only on QoL at follow-up at week 26. No serious side effects were observed (Murray et al 2005).

A study by Lauritzen and coworkers (1994) compared the efficacy of two TCAs, desipramine against imipramine, both drugs combined with mianserin. The doses of the drugs were flexible, with side-effects as a guide during treatment. Imipramine treatment was more effective than desipramine in reducing depressive symptoms evaluated by means of Melancholia Scale, but not by means of HDRS. However, a large proportion (35%) of the sample was lost in the follow-up, particularly in the desipramine group (Lauritzen et al 1994).

Lastly, Reding and colleagues (1986) evaluated the response of depressive symptoms to trazodone in a controlled trial vs. placebo. They showed that trazodone treated patients had a tendency to increase in autonomy in ADL measured by the Barthel index compared to patients treated with placebo. However, a high drop-out rate due to side effects was observed in both groups of patients. In particular, twelve patients discontinued the study: six patients from the trazodone group (4 sedation, 1 eye discomfort, 1 refusal), but also six patients in placebo group (4 sedation, 1 nausea, 1 dizziness). Moreover, because of the particular study design, it was not possible to compare the improvement in depression scores of both groups.

Other studies

There are other studies that evaluated the impact of different type of ADs on functional outcome and rehabilitation results. Today, AD therapy may be beneficial to functional recovery but it cannot abolish the detrimental effect of depression on functional outcome (Gonzalez-Torrecillas et al 1995; Dam et al 1996; Miyai and Reding 1998; Gainotti et al 2001).

In a nonrandomized study published in 1995, Gonzalez-Torrecillas and colleagues showed that treated PSD patients (with nortriptyline or fluoxetine) had not only a better mood, but also a better functional and cognitive outcome compared to untreated PSD patients. Moreover, the study was nonblinded: fluoxetine was given to patients with cardiac defects and nortriptyline to those without. Both drugs made similar gains in both mood and functional ability (Gonzalez-Torrecillas et al 1995).

Some years later Gainotti and colleagues (2001) confirmed that functional recovery of nontreated depressed patients was poorer than the nondepressed and the depressed but treated patients.

Dam and colleagues (1996) observed that patients treated with fluoxetine had better rehabilitation results in comparison with those of patients treated with norepinephrine reuptake blocker maprotiline or placebo. These effects were not related to the specific antidepressant action. Moreover, both groups treated with Ads showed a significant baseline to endpoint mean improvement in HDRS score (fluoxetine 30%, maprotiline 18%). Mean improvement in placebo group was 12%.

This favorable role of fluoxetine on functional status was confirmed also by another study, in which patients treated with fluoxetine or trazodone showed a better improvement on functional independence measure compared with patients treated with desipramine (Miyai and Reding 1998).

Since serotonin (5-HT) stimulates motor function, there are some studies that investigated the hypothesis that a pharmacological potentiation of 5-HT neurotransmission may improve motor function in healthy subjects and recovery in poststroke patients (Pariente et al 2001; Loubinoux et al 2002). In particular, in a double-blind, crossover, placebo-controlled study on 8 patients with pure motor hemiparesis, a single dose of fluoxetine was able to significantly improve motor skills of the affected side (Pariente et al 2001). However, other experimental reports (after focal ischemia in rats) did not confirm these adjuvant action of fluoxetine on recovery of motor function (Windle and Corbett. 2005).

ADs may reduce post stroke mortality. In a 9 year follow-up study, treatment with fluoxetine or nortriptyline for 12 weeks during the first 6 months after stroke significantly increased the survival of both depressed and nondepressed patients (Jorge et al 2003).

Lastly, there are few studies on the usefulness of new dual-agents SNRIs (serotonin and norepinephrine reuptake inhibitors), as venlafaxine or milnacipran and duloxetine (Dahmen et al 1999; Yamakawa et al 2005), but methodological problems (open-label studies and with small case-series) reduce the power of these data.

Prevention of PSD

A recent Cochrane review, evaluating data from nine trials (11 comparisons) involving different pharmaceutical agents, and three trials of psychotherapy, found no clear effect of either pharmacotherapy or psychotherapy on the prevention of depressive illness or disability (Anderson et al 2004). Moreover, data from a more recent trial showed that sertraline treatment, 50 mg/day, had no advantage in comparison to placebo in preventing PSD (Almeida et al 2006).

A more recent meta-analysis published in 2007, evaluating 10 randomized clinical trials, with a total of 703 nondepressed stroke patients, found that ADs prophylaxis was associated with a significant reduction in the occurrence rate of newly developed poststroke depression (12.54% in the treated group vs 29.17% in control group) (Chen et al 2007).

Length of treatment

At present, there is no scientific evidence regarding the optimal length of treatment of PSD. Many of the available trials terminate at six weeks, but withdrawal at this stage may result in relapse. In a recent review, Turner-Stokes and Hassan (2002) recommended carrying on AD treatment for 4–6 months, followed by slow withdrawal. The same length of AD is recommended by the Italian Guidelines for stroke management SPREAD (Stroke Prevention and Awareness Diffusion), but the power of this recommendation is weak (grade GPP, based on the clinical experience of the guideline development group, without research evidence) (SPREAD 2005).

Conclusions

Presently, there are still too many questions about PSD and too few answers. Crucial unresolved issues are essentially related to correct diagnostic and therapeutic approaches. There is clear evidence that an AD treatment may improve depression but it is unable to produce a full clinical remission or prevent the onset of diagnosable depressive illness. Moreover, data available regarding the choice or the length of optimal treatment are still not conclusive.

Because the benefits of AD therapy are potentially great, not only on mood but also on functional recovery, there is a pressing need for further research in this area of stroke medicine.